ClinicaliQ Trial Snapshot
- A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement — Recruiting • Phase II • Oncology • NCT07359820.
- Drug and target: Lirafugratinib, a selective FGFR2 inhibitor, is being tested in previously treated patients with advanced/metastatic solid tumours (excluding cholangiocarcinoma) that harbour FGFR2 fusion or rearrangement mutations.
- Patient eligibility: Adults with unresectable, locally advanced or metastatic solid tumours who have received prior treatment and carry FGFR2 genetic alterations are eligible; this represents a genotype-driven rather than tumour-type-driven approach.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The goal of this clinical trial is to evaluate if lirafugratinib is efficacious and safe to treat adult patients with previously treated, unresectable, locally advanced or metastatic solid tumors (excluding cholangiocarcinoma) harboring FGFR2 fusion or rearrangement. Participants will: * Take lirafugratinib regularly as instructed by their study doctor. * Visit the clinic as instructed for checkups and tests. * Keep a diary recording each time a dose of lirafugratinib is taken.
Eligibility Snapshot
- : * Unresectable, locally advanced, or metastatic solid tumor (other than CCA). * Documented FGFR2 gene fusion or rearrangement per local testing of blood and/or tumor. * Patient must have measurable disease per RECIST v1.1• Patient has ECOG performance status of 0-1. * Previously (>30 days) treated with ≥1 line of systemic therapy including chemotherapy (e.g., gemcitabine/cisplatin), immunotherapy, radiation therapy, or other approved therapies. * Subject has not received prior treatment with an FGFRi.
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.